http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2013525469-A
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C323-32 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-137 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-145 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-661 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-661 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C323-32 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07F9-09 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P37-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-145 |
| filingDate | 2011-05-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2013-06-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | JP-2013525469-A |
| titleOfInvention | Administration regimen of diaryl sulfide derivatives |
| abstract | Formula (I), optionally for use in a method of treating an autoimmune condition: [Where, X is O, S, SO or SO 2 ; R 1 is halogen, trihalomethyl, —OH, C 1-7 alkyl, C 1-4 alkoxy, trifluoromethoxy, phenoxy, cyclohexylmethyloxy, pyridylmethoxy, cinnamyloxy, naphthylmethoxy, phenoxymethyl, —CH 2 —. OH, —CH 2 —CH 2 —OH, C 1-4 alkylthio, C 1-4 alkylsulfinyl, C 1-4 alkylsulfonyl, benzylthio, acetyl, nitro or cyano, or phenyl, phenyl C 1-4 alkyl or phenyl -C 1-4 alkoxy, halogen case each phenyl group may be substituted by CF 3, C 1-4 alkyl or C 1-4 alkoxy; R 2 is H, halogen, trihalomethyl, C 1-4 alkoxy, C 1-7 alkyl, phenethyl or benzyloxy; R 3 is H, halogen, CF 3 , OH, C 1-7 alkyl, C 1-4 alkoxy, benzyloxy, phenyl or C 1-4 alkoxymethyl; Each of R 4 and R 5 is independently H or formula (a) The basis of Wherein each of R 8 and R 9 is independently H or C 1-4 alkyl optionally substituted with halogen; n is an integer of 1-4. ] Or a pharmaceutically acceptable salt, hydrate, solvate, isomer or prodrug thereof; Or formula (II) [Where, R 1a is halogen, trihalomethyl, C 1-4 alkyl, C 1-4 alkoxy, C 1-4 alkylthio, C 1-4 alkylsulfinyl, C 1-4 alkyl-sulfonyl, aralkyl, optionally substituted. Is phenoxy or aralkyloxy; R 2a is H, halogen, trihalomethyl, C 1-4 alkyl, C 1-4 alkoxy, aralkyl or aralkyloxy; R 3a is H, halogen, CF 3 , C 1-4 alkyl, C 1-4 alkoxy, C 1-4 alkylthio or benzyloxy; R 4a is H, C 1-4 alkyl, phenyl, optionally substituted benzyl or benzoyl, or lower aliphatic C 1-5 acyl; R 5a is H, monohalomethyl, C 1-4 alkyl, C 1-4 alkoxy-methyl, C 1-4 alkyl-thiomethyl, hydroxyethyl, hydroxypropyl, phenyl, aralkyl, C 2-4 alkenyl or -alkynyl; R 6a is H or C 1-4 alkyl; R 7a is H, C 1-4 alkyl or a group of formula (a) as defined above; X a is O, S, SO or SO 2 ; n a is an integer of 1 to 4. ] Or a pharmaceutically acceptable salt, hydrate, solvate, isomer or prodrug thereof, Here, the compound of formula (I) or (II) is administered at a dose lower than the standard daily dose of the compound during the initial treatment, and then optionally in a standard daily dose. What is increased up to. |
| priorityDate | 2010-05-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 64.